Skip to main content

Zeposia

Generic name: ozanimod [ oh-ZAN-i-mod ]
Dosage form: oral capsule (0.23 mg; 0.46 mg; 0.92 mg)
Drug class: Selective immunosuppressants

Medically reviewed by Melisa Puckey, BPharm. Last updated on May 1, 2023.

What is Zeposia?

Zeposia (ozanimod) capsules are used to treat adults with types relapsing forms of multiple sclerosis (MS) and moderately to severely active ulcerative colitis (UC). Zeposia helps to reduce the relapse rate and the number and size of brain lesions in multiple sclerosis. For ulcerative colitis, Zeposia is used to reduce symptoms, and it can also help achieve and maintain remission.

Zeposia is FDA-approved to treat adults with moderately to severely active ulcerative colitis and also FDA-approved to treat relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Multiple sclerosis and ulcerative colitis are both autoimmune disorders where the immune cells (lymphocytes) are thought to incorrectly start attacking your healthy tissue, thinking that it is a foreign substance. In multiple sclerosis, the immune system attacks and damages the myelin sheath that covers the nerves in the brain and spinal cord (CNS). This disrupts the brain from sending signals to the rest of the body and causes symptoms including numbness and tingling in the face, arms, feet, and legs, balance issues and trouble walking, vision problems, bowel and bladder problems, fatigue, and problems thinking and concentrating.

In ulcerative colitis, the immune system attacks and causes inflammation in the lining of the colon which causes the symptoms of abdominal pain, rectal bleeding, bowel urgency, diarrhea, and tiredness. 

How does Zeposia work?

Zeposia is thought to work by preventing immune cells (lymphocytes) from entering the intestines and central nervous system (CNS). It does this by trapping the immune cells in the lymph nodes, which may stop them from causing harmful inflammation in the CNS (in the case of multiple sclerosis) and the colon (in the case of ulcerative colitis). By reducing inflammation that would have been caused by the lymphocytes, the symptoms of these conditions may improve. 

Zepsosia is from a class of medicines called sphingosine 1-phosphate (S1P) receptor modulators. Zeposia has its effect by binding to the S1P1 receptors on a range of cells which is thought to stop the lymphocytes from being able to leave the lymph nodes.

Warnings

Infections: You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, flu symptoms, feeling very tired, cough, rash, painful and frequent urination, neck stiffness, increased sensitivity to light. Your risk of infection could last for 3 months after you stop taking this medicine.

Heart rate: This medicine can slow your heart rate when you start taking it. Tell your doctor if you have slow heartbeats, chest pain, shortness of breath, or feeling like your heart is skipping beats.

Progressive multifocal leukoencephalopathy (PML): Zeposia can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. PML is more likely to happen in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including weakness on one side of your body, loss of coordination in your arms or legs, decreased strength, problems with balance, changes in your vision, changes in your thinking or memory, confusion or changes in your personality.

Before taking this medicine

You should not use Zeposia if you are allergic to the active ingredient ozanimod or any of the inactive ingredients. To check for a complete list of ingredients, click here: Zeposia ingredients

You should not use Zeposia if you have certain serious heart conditions, especially:

Some heart rhythm medications can cause unwanted or dangerous effects when used with this medicine. Your doctor may change your treatment plan if you also use amiodarone, disopyramide, dofetilide, dronedarone, ibutilide, procainamide, quinidine, or sotalol.

Do not use this medicine if you have used an MAO inhibitor in the past 14 days, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, or tranylcypromine. Wait at least 14 days after stopping an MAO inhibitor before you take Zeposia.

You should not receive live vaccines during treatment with Zeposia, for at least 1 month before starting treatment, and for 3 months after you stop treatment. Vaccines may not work as well when given during treatment with Zeposia.

Tell your doctor if you have received any vaccine within the past 30 days or if you are scheduled to receive a vaccine.

Tell your doctor if you have a fever or infection, or if you have ever had:

Before taking this medicine, you should have a complete blood count, a cardiac evaluation, liver function tests, and a ophthalmic assessment. Your doctor will check your current or prior medication, your vaccination history, and whether you have a confirmed history of chickenpox.

Pregnancy

Zeposia may harm an unborn baby. Tell your doctor if you are planning a pregnancy or are pregnant. Use effective birth control while using this medicine and for at least 3 months after your last dose.

If you become pregnant while taking Zeposia pregnant, talk to your healthcare provider about registering with the Pregnancy Registry. The purpose of this registry is to collect information about your health and your baby's health.

Breastfeeding

It is not known if Zeposia passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you taking this medicine.

How should I take Zeposia?

Take Zeposia exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.

This medicine can slow your heart rate when you start taking it. Before your first dose, your heart function will be checked using an electrocardiograph or ECG (sometimes called an EKG).

Zeposia comes in a 7-day starter pack containing capsules of different colors and strengths. You should follow the dosing schedule as prescribed by your doctor. This may lower the risk of side effects.

You may get infections more easily, even serious or fatal infections. You will need frequent medical tests, and your risk of infection could last for 3 months after you stop taking this medicine.

If you get an infection, further doses may be delayed until your infection clears up.

Always ask your doctor before you stop taking this medicine for any reason. Your symptoms may return and become worse than before or during treatment with this medicine. Tell your doctor if you have any signs of worsening symptoms.

Zeposia Instructions

Follow the dose schedule in the table below. This may reduce the risk of slowing of the heart rate.

Days 1-4

Take 0.23 mg (capsule in light grey color) 1 time a day

Days 5-7

Take 0.46 mg (capsule in half-light grey and half-orange color) 1 time a day

Days 8 and thereafter

Take 0.92 mg (capsule in orange color) 1 time a day

Dosing information

Usual Adult Dose for Multiple Sclerosis

Dose titration regimen

Maintenance dose:

Uses:

Usual Adult Dose for Ulcerative Colitis

Dose titration regimen

Maintenance dose

Uses:

Zeposia is available as

Capsules:

What happens if I miss a dose?

Call your doctor for instructions. If you miss 1 or more doses in the first 2 weeks of treatment, you may need to start a new 7-day starter pack.

If you miss a dose after the first 2 weeks: Skip the missed dose and use your next dose at the regular time.

Do not take two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Zeposia?

Avoid getting up too fast from a sitting or lying position, or you may feel dizzy.

Avoid getting a vaccine without first asking your doctor. While you are taking this medicine, a "live" vaccine may not fully protect you from disease and you could develop an infection. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), and zoster (shingles). You should not receive a live vaccine within 1 month before taking Zeposia, while taking it, and for at least 3 months after you stop taking it.

Zeposia side effects

Get emergency medical help if you have signs of an allergic reaction to Zeposia: hives, rash; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

Common Zeposia side effects may include

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Zeposia?

Zeposia can cause a serious heart problem and your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.

Tell your doctor about all your other medicines, especially:

Zeposia can have long lasting effects on your body, especially on your immune system. For at least 4 weeks after your last dose, tell any doctor who treats you that you have used this medicine.

This list is not complete and many other medications may also interact with Zeposia so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. To check for interactions with Zeposia click on the link below.

Ingredients

Active ingredient: ozanimod

Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.

The capsule shell contains: black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.

Storage

Manufacturer

Marketed by: Bristol-Myers Squibb Company, Princeton, NJ 08543 USA.

Zeposia® is a trademark of Celgene Corporation, a Bristol-Myers Squibb company.

Popular FAQ

Zeposia (ozanimod) is a not a biologic it is a small-molecule S1P receptor modulator that binds specifically to two S1P receptors and is thought to block the ability of lymphocytes to escape out of the lymph nodes reducing their numbers in the blood, gut, CNS, and inflamed tissue. Continue reading

Ozanimod (Zeposia) works quickly in people with MS, within a few months, although it may take up to a year for the full effects of significantly less disease progression, fewer relapses, and less brain atrophy than standard care to be seen. For people with UC, improvements in symptoms such as rectal bleeding and stool frequency were seen as early as week 2 and significant differences in clinical remission, clinical response, and endoscopic improvement compared to placebo were noted within 10 weeks of starting ozanimod. Continue reading

The reason ozanimod may slow down your heart rate temporarily when you first start taking it is thought to be due to the action of ozanimod binding to one of the S1P receptors' subunits, S1P1R, which also has an effect of potassium channels in cardiac muscle cells. This reduces how responsive the cardiac cells are and reduces their firing rate, which slows down the heart. Continue reading

More FAQ

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.